Skip to main content
European Commission logo print header

Revolutionary vaccines to prevent pandemic and seasonal outbreaks of respiratory viral infections: The best-in-class UNIVERSAL multi-season influenza vaccine

Project description

Novel universal vaccine against seasonal flu outbreaks

Seasonal flu and other respiratory RNA viral infections affect ~10 % of the global population every year. Existing prophylactic vaccination has limited efficacy and requires updates each flu season or pandemic outbreak due to the high mutation rate of the viral surface proteins targeted by current vaccines. French clinical-stage biotech OSIVAX aims to develop novel vaccines to prevent respiratory viral infections for multiple seasons and outbreaks. OSIVAX has developed OVX836, a universal flu vaccine candidate based on a proprietary immune-boosting technology that triggers targeted and durable immune responses. OVX836 circumvents the annual vaccination updates by targeting an intraviral protein conserved across all influenza strains. The goal of the EU-funded OSIRIX project is to prepare OVX836 for the clinical proof-of-efficacy milestone.

Objective

While an ongoing pandemic outbreak of coronavirus (COVID-19) is having enormous impact on global societies, a quest for effective vaccination becomes of unprecedented importance to save lives and economies globally.
Symptomatic flu, another respiratory RNA viral infection, affects ~10% of global population every year and leads to regular pandemic outbreaks. Existing prophylactic vaccination requires updates each flu season or pandemic outbreak, and has a strikingly limited efficacy (40% on average, as low as 9% in elderly). This is mainly due to a rapid mutation rate of surface viral proteins that are targeted by the current vaccines. Governments, institutions and vaccine community urgently seek for a universal flu vaccine that would provide a multi-season protection against all seasonal and emerging pandemic viral strains.
OSIVAX, a French clinical stage innovative biotech, strives to develop vaccines able to prevent respiratory viral infections across multiple seasons and outbreak. OSIVAX has developed OVX836, a best-in-class, game-changing universal flu vaccine candidate.
OVX836 is based on oligoDOM®, a proprietary immune-boosting technology that triggers powerful, targeted and durable immune responses involving activation of specific immune response killing infected cells. OVX836 circumvents the need for annual vaccination updates by targeting an intraviral protein that is highly conserved across all influenza strains.
OVX836 has a potential to disrupt the flu vaccine market currently dominated by single-season vaccines. The revolutionary universal flu vaccine is predicted to have a blockbuster potential (>€2.5 billion). OSIVAX’s experienced team aims to get OVX836 ready for the clinical proof-of-efficacy milestone (Phase IIb) that will position the company for >€500M licensing deal with a big pharma in 2024.

At the moment, OSIVAX leverages this revolutionary clinical-stage technology to initiate the development of a universal vaccine against corona

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-EIC-SMEInst-2018-2020-3

æ

Coordinator

OSIVAX SAS
Net EU contribution
€ 2 461 122,48
Address
4 rue de copenhague
75008 Paris
France

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 1 054 766,77